INTI
Price
$0.06
Change
-$0.00 (-0.00%)
Updated
May 22 closing price
Capitalization
10.15M
IVBXF
Price
$7.39
Change
+$0.31 (+4.38%)
Updated
May 23 closing price
Capitalization
12.26B
Interact to see
Advertisement

INTI vs IVBXF

Header iconINTI vs IVBXF Comparison
Open Charts INTI vs IVBXFBanner chart's image
Inhibitor Therapeutics
Price$0.06
Change-$0.00 (-0.00%)
Volume$20.68K
Capitalization10.15M
Innovent Biologics
Price$7.39
Change+$0.31 (+4.38%)
Volume$200
Capitalization12.26B
INTI vs IVBXF Comparison Chart
Loading...
View a ticker or compare two or three
VS
INTI vs. IVBXF commentary
May 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INTI is a Hold and IVBXF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 24, 2025
Stock price -- (INTI: $0.06 vs. IVBXF: $7.08)
Brand notoriety: INTI and IVBXF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INTI: 58% vs. IVBXF: 72%
Market capitalization -- INTI: $10.15M vs. IVBXF: $12.26B
INTI [@Biotechnology] is valued at $10.15M. IVBXF’s [@Biotechnology] market capitalization is $12.26B. The market cap for tickers in the [@Biotechnology] industry ranges from $298.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INTI’s FA Score shows that 0 FA rating(s) are green whileIVBXF’s FA Score has 0 green FA rating(s).

  • INTI’s FA Score: 0 green, 5 red.
  • IVBXF’s FA Score: 0 green, 5 red.
According to our system of comparison, IVBXF is a better buy in the long-term than INTI.

Price Growth

INTI (@Biotechnology) experienced а +5.18% price change this week, while IVBXF (@Biotechnology) price change was +19.11% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.05%. For the same industry, the average monthly price growth was +3.15%, and the average quarterly price growth was -3.91%.

Reported Earning Dates

INTI is expected to report earnings on May 14, 2025.

Industries' Descriptions

@Biotechnology (+1.05% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

FUNDAMENTALS
Fundamentals
IVBXF($12.3B) has a higher market cap than INTI($10.1M). IVBXF YTD gains are higher at: 64.222 vs. INTI (-1.997).
INTIIVBXFINTI / IVBXF
Capitalization10.1M12.3B0%
EBITDA-3.07MN/A-
Gain YTD-1.99764.222-3%
P/E RatioN/AN/A-
Revenue0N/A-
Total Cash6.38MN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
INTI: Fundamental Ratings
INTI
OUTLOOK RATING
1..100
89
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
PROFIT vs RISK RATING
1..100
95
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
54
P/E GROWTH RATING
1..100
87
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RSI
ODDS (%)
Stochastic
ODDS (%)
Momentum
ODDS (%)
MACD
ODDS (%)
TrendWeek
ODDS (%)
TrendMonth
ODDS (%)
Advances
ODDS (%)
Declines
ODDS (%)
BollingerBands
ODDS (%)
Aroon
ODDS (%)
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CTSOX37.390.16
+0.43%
Calamos Timpani Small Cap Growth R6
ARTYX23.930.03
+0.13%
Artisan Developing World Investor
SWMIX22.56N/A
N/A
Schwab International Opportunities
DDDCX16.96N/A
N/A
13D Activist C
RFNGX82.96-0.28
-0.34%
American Funds Fundamental Invs R6

INTI and

Correlation & Price change

A.I.dvisor tells us that INTI and QRON have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INTI and QRON's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INTI
1D Price
Change %
INTI100%
N/A
QRON - INTI
24%
Poorly correlated
N/A
DWTX - INTI
23%
Poorly correlated
-1.69%
IVEVF - INTI
17%
Poorly correlated
N/A
IVBXF - INTI
11%
Poorly correlated
+4.45%
HSTC - INTI
8%
Poorly correlated
N/A
More

IVBXF and

Correlation & Price change

A.I.dvisor tells us that IVBXF and WXXWY have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IVBXF and WXXWY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IVBXF
1D Price
Change %
IVBXF100%
+4.45%
WXXWY - IVBXF
22%
Poorly correlated
+1.04%
ONC - IVBXF
22%
Poorly correlated
+2.09%
MDWD - IVBXF
20%
Poorly correlated
+0.15%
IVEVF - IVBXF
15%
Poorly correlated
N/A
INTI - IVBXF
11%
Poorly correlated
N/A
More